Zenotech Laboratories Ltd
ZENOTECHZenotech Laboratories Ltd
ZENOTECHPrice Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
68.40 | 5.03 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
50.62 | 6.47 | 0.53% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
The Company is a pharmaceutical specialty generic injectables company engaged in the area of manufacturing biotechnology products. The Company's injectables product portfolio primarily serves therapy areas, such as oncology and anesthesiology.
Peers
Compare with peersBiocon Ltd
Panacea Biotec Ltd
Hester Biosciences Ltd
Vivo Bio Tech Ltd
Transgene Biotek Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 2.10 | 4.16 | 13.51 | 17.74 | 33.56 | 22.86 | 37.20 | 43.50 | 41.83 | 42.37 | ||||||||||
Raw Materials | 2.00 | 1.52 | 0.81 | 0.71 | 0.50 | 0.03 | 0.00 | 0.06 | 0.00 | 25.85 | ||||||||||
Power & Fuel Cost | 0.98 | 1.94 | 4.24 | 3.68 | 3.29 | 3.12 | 3.25 | 3.79 | 2.69 | |||||||||||
Employee Cost | 2.25 | 3.02 | 5.07 | 4.98 | 5.76 | 6.49 | 7.10 | 7.88 | 9.46 | |||||||||||
Selling & Administrative Expenses | 3.43 | 2.93 | 3.57 | 2.21 | 1.75 | 1.62 | 1.91 | 2.00 | 2.33 | |||||||||||
Operating & Other expenses | 1.07 | 3.24 | 5.32 | 4.97 | 5.74 | 4.80 | 6.84 | 7.99 | 9.13 | |||||||||||
EBITDA | -7.63 | -8.49 | -5.50 | 1.19 | 16.52 | 6.80 | 18.10 | 21.78 | 18.22 | 16.52 | ||||||||||
Depreciation/Amortization | 3.96 | 3.87 | 3.90 | 4.20 | 4.85 | 6.46 | 6.97 | 7.17 | 7.09 | 6.95 | ||||||||||
PBIT | -11.59 | -12.36 | -9.40 | -3.01 | 11.67 | 0.34 | 11.13 | 14.61 | 11.13 | 9.57 | ||||||||||
Interest & Other Items | 7.55 | 7.50 | 2.45 | 0.12 | 0.89 | 1.55 | 1.22 | 0.11 | 0.00 | — | ||||||||||
PBT | -19.14 | -19.86 | -11.85 | -3.13 | 10.78 | -1.21 | 9.91 | 14.50 | 11.13 | 9.57 | ||||||||||
Taxes & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -12.27 | 2.92 | 2.84 | 2.91 | ||||||||||
Net Income | -19.14 | -19.86 | -11.85 | -3.13 | 10.78 | -1.21 | 22.18 | 11.58 | 8.29 | 6.66 | ||||||||||
EPS | -5.28 | -5.47 | -2.44 | -0.51 | 1.77 | -0.20 | 3.63 | 1.90 | 1.36 | 1.09 | ||||||||||
DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CareBiotechnology
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Zenotech Laboratories Ltd | 54.95 | 5.03 | — |
Biocon Ltd | 39.40 | 1.59 | 0.15% |
Panacea Biotec Ltd | -2,231.20 | 3.09 | — |
Hester Biosciences Ltd | 119.20 | 7.43 | 0.23% |
Price Comparison
Compare ZENOTECH with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
ZENOTECH has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Net profit of Zenotech Laboratories declined 52.30% to Rs 1.35 crore in the quarter ended September 2024 as against Rs 2.83 crore during the previous quarter ended September 2023. Sales declined 16.75% to Rs 8.75 crore in the quarter ended September 2024 as against Rs 10.51 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales8.7510.51 -17 OPM %27.5452.43 - PBDT2.755.70 -52 PBT1.003.89 -74 NP1.352.83 -52 Powered by Capital Market - Live
Zenotech Laboratories will hold a meeting of the Board of Directors of the Company on 23 October 2024.Powered by Capital Market - Live
Zenotech Laboratories announced that the 35th Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
Zenotech Laboratories standalone net profit declines 10.42% in the June 2024 quarter
Net profit of Zenotech Laboratories declined 10.42% to Rs 1.29 crore in the quarter ended June 2024 as against Rs 1.44 crore during the previous quarter ended June 2023. Sales rose 7.89% to Rs 8.89 crore in the quarter ended June 2024 as against Rs 8.24 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales8.898.24 8 OPM %38.7044.42 - PBDT3.783.86 -2 PBT2.052.06 0 NP1.291.44 -10 Powered by Capital Market - Live
Zenotech Laboratories will hold a meeting of the Board of Directors of the Company on 26 July 2024.Powered by Capital Market - Live
Zenotech Laboratories standalone net profit declines 61.77% in the December 2022 quarter
Stocks to Watch: Adani Enterprises, Bajaj Finance, Maruti Suzuki, Tata Motors
Zenotech Laboratories standalone net profit rises 191.58% in the September 2022 quarter
Zenotech Laboratories standalone net profit rises 7.71% in the June 2022 quarter
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 18.72%, vs industry avg of 19.21%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.26% to 0.25%